Airfinity launches free obesity market newsletter to provide critical updates to senior leaders

Current estimates indicate 650 million people are obese globally, and the US alone spends $173 Bn/year in obesity-related healthcare costs. This demonstrates the size of the anti-obesity market and impact new treatments could have on the global landscape.

Airfinity's new obesity market intelligence newsletter provides a free, curated summary of the latest news, commentary, and scientific results delivered to your inbox every week. Our team monitors and assesses the entire anti-obesity landscape, spanning hundreds of data sources and channels, in order to get you the most important information and give answers to the critical questions:

Clinical Developments

What does the current pipeline look like, from pre-clinical through to post-approval? What are the latest partnerships to be announced?

Commercial Developments

What does current manufacturing capacity look like and how might anticipated demand impact future production efforts?

Regulatory Developments

What are the new submissions and approvals in the space? Are we seeing any shifts in drug pricing regulations, reimbursement policies, or negotiations between pharmaceutical companies and payers? What is being done to control and prevent counterfeit or substandard medications from entering the market?

Disease Outcomes

What is the latest analysis and understanding around the wider economic impact of current anti-obesity drugs, and their role in reducing disease burden across other CVRM diseases?

Register for the free newsletter here.